Most interestingly, high intratumoral levels of GAMs of all M/M markers (including both presumptive M2 markers CD163 and CD206) were associated with a better overall survival in IDH1R132H‐non‐mutant GBM patients (Figure 3B, Figure S4A) independent of the aforementioned expression levels in WHO grades II–IV with a tendency toward highest GAM amounts in GBM patients as compared to lower grade diffuse astrocytomas (Figure 2B, Figure S3). The gene discussed is CD163; the disease is glioblastoma.